102 related articles for article (PubMed ID: 25168905)
21. Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range.
Vukovic I; Djordjevic D; Bojanic N; Babic U; Soldatovic I
Int Braz J Urol; 2017; 43(1):48-56. PubMed ID: 28124526
[TBL] [Abstract][Full Text] [Related]
22. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
23. Role of
Jiménez Londoño GA; García Vicente AM; Amo-Salas M; Fúnez Mayorga F; López Guerrero MA; Talavera Rubio MP; Gutierrez Martin P; González García B; de la Torre Pérez JA; Soriano Castrejón ÁM
Rev Esp Med Nucl Imagen Mol; 2017; 36(4):241-246. PubMed ID: 28330596
[TBL] [Abstract][Full Text] [Related]
24. Contrast-enhanced ultrasonography for the detection and characterization of prostate cancer: correlation with microvessel density and Gleason score.
Jiang J; Chen Y; Zhu Y; Yao X; Qi J
Clin Radiol; 2011 Aug; 66(8):732-7. PubMed ID: 21524418
[TBL] [Abstract][Full Text] [Related]
25. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
26. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
28. Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?
Makarov DV; Sanderson H; Partin AW; Epstein JI
J Urol; 2002 Jun; 167(6):2440-2. PubMed ID: 11992053
[TBL] [Abstract][Full Text] [Related]
29. Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.
Zhang Q; Wang W; Zhang B; Shi J; Fu Y; Li D; Guo S; Zhang S; Huang H; Jiang X; Zhou W; Guo H
Int Urol Nephrol; 2017 Mar; 49(3):439-448. PubMed ID: 28005230
[TBL] [Abstract][Full Text] [Related]
30. Preoperative PSA is still predictive of cancer volume and grade in late PSA era.
Figler BD; Reuther AM; Dhar N; Levin H; Magi-Galluzzi C; Zhou M; Klein EA
Urology; 2007 Oct; 70(4):711-6. PubMed ID: 17991542
[TBL] [Abstract][Full Text] [Related]
31. Serum monocyte fraction of white blood cells is increased in patients with high Gleason score prostate cancer.
Hayashi T; Fujita K; Tanigawa G; Kawashima A; Nagahara A; Ujike T; Uemura M; Takao T; Yamaguchi S; Nonomura N
Oncotarget; 2017 May; 8(21):35255-35261. PubMed ID: 27823973
[TBL] [Abstract][Full Text] [Related]
32. Transperineal prostate biopsy detects significant cancer in patients with elevated prostate-specific antigen (PSA) levels and previous negative transrectal biopsies.
Dimmen M; Vlatkovic L; Hole KH; Nesland JM; Brennhovd B; Axcrona K
BJU Int; 2012 Jul; 110(2 Pt 2):E69-75. PubMed ID: 22093091
[TBL] [Abstract][Full Text] [Related]
33. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
Caster JM; Falchook AD; Hendrix LH; Chen RC
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?
Calabria F; Chiaravalloti A; Tavolozza M; Ragano-Caracciolo C; Schillaci O
Nucl Med Commun; 2013 Aug; 34(8):733-40. PubMed ID: 23680652
[TBL] [Abstract][Full Text] [Related]
35. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
36. Gleason inflation 1998-2011: a registry study of 97,168 men.
Danneman D; Drevin L; Robinson D; Stattin P; Egevad L
BJU Int; 2015 Feb; 115(2):248-55. PubMed ID: 24552193
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer volume -- can it be predicted preoperatively?
Alschibaja M; Wegner M; Massmann J; Funk A; Hartung R; Paul R
Urol Int; 2005; 75(4):354-9. PubMed ID: 16327306
[TBL] [Abstract][Full Text] [Related]
38. Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era.
Tosoian JJ; Chappidi M; Feng Z; Humphreys EB; Han M; Pavlovich CP; Epstein JI; Partin AW; Trock BJ
BJU Int; 2017 May; 119(5):676-683. PubMed ID: 27367645
[TBL] [Abstract][Full Text] [Related]
39. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
40. Transperineal Template-guided Mapping Biopsy Identifies Pathologic Differences Between Very-Low-risk and Low-risk Prostate Cancer: Implications for Active Surveillance.
Merrick GS; Delatore A; Butler WM; Bennett A; Fiano R; Anderson R; Adamovich E
Am J Clin Oncol; 2017 Feb; 40(1):53-59. PubMed ID: 25068472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
